The global monoclonal gammopathy of undetermined significance (MGUS) management market is estimated to generate a market value of US$ 27 million in 2023 and a market value of US$ 53.11 million by 2033, growing at a CAGR of 7% from 2023 to 2033. The market for Monoclonal Gammopathy of Undetermined Significance (MGUS) Management grew at a 4% CAGR from 2018 to 2022.
Request a Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16694
According to American Cancer Society estimates in January 2022, about 60,650 new cases of leukemia and 24,000 deaths from leukemia and there were around 11,450 deaths due to acute myeloid leukemia in the United States in the year 2022. The increasing demand for these treatments is expected to lead to the development of new and innovative treatments, which will drive the growth of the market in the coming years. The market is likely to witness significant growth due to the increasing incidence of blood cancers and the increasing focus on improving treatment options for patient.
As a result of positive growth, various start-ups are entering the market. For instance, Orca Bio is a developer of allogeneic cell therapy for the treatment of blood, genetic and immune diseases. The company uses its proprietary OrcaSort technology to isolate and purify stem cells and immune cells used in hematopoietic cell grafts. The technology is optimized for performance and is designed to fit seamlessly into the clinical processing of apheresis products, providing a scalable and high-precision manufacturing platform.
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, government initiatives and an increase in the number of research partnerships are boosting market growth across North America. Asia Pacific is a growing market due to a shift towards point-of-care healthcare. The increasing number of hospitals in India and China presents a promising market opportunity globally.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16694
Key Takeaways from the Market Study
- From 2018 to 2022, the monoclonal gammopathy of undetermined significance management market grew at a CAGR of 4%.
- The global monoclonal gammopathy of undetermined significance management market is expected to grow with a 7% CAGR from 2023 to 2033.
- As of 2033, the monoclonal gammopathy of undetermined significance management market is expected to reach US$ 53.11 Million
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess a 40% market share in the Monoclonal gammopathy of undetermined significance management market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering monoclonal gammopathy of undetermined significance management.” says an FMI analyst
Market Competition
Key players in the market include pharmaceutical companies such as Janssen Biotech, Inc., Pfizer, Inc., Amgen, Inc., Roche Holding AG, Celgene Corporation (Acquired by Bristol-Myers Squibb), Novartis AG, Merck & Co., Inc., Sanofi S.A, Takeda Pharmaceutical Company Limited and Gilead Sciences, Inc. along with healthcare providers and technology companies among other global players.
- In January 2022, Kura Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on their KOMET-001 Phase 1b study of the drug KO-539 for the treatment of relapsed or refractory acute myeloid leukemia (AML). This allows the company to proceed with the study to evaluate the safety and efficacy of KO-539 in patients with AML.
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-16694
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Monoclonal gammopathy of undetermined significance management market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Key Segments Profiled in the Monoclonal Gammopathy of Undetermined Significance (MGUS) Management Industry Survey
Drug Class:
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Diagnosis:
- Blood Tests
- Urine Tests
- Imaging Tests
- Bone Marrow Tests
End Users:
- Hospitals
- Speciality Centers
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
